238 x 160
Microbiome Sequencing Services Market Intelligence Report, Growth Drivers & Forecast, 2026-2035
Market Insight: Sequencing Moves From Microbial Identification Toward Functional Intelligence
The global microbiome sequencing services market is projected to expand from USD 1.96 billion in 2026 to USD 5.25 billion by 2036, representing a 10.36% CAGR during 2027–2036. The underlying opportunity is increasingly shifting beyond simply identifying microbial populations toward understanding how microbial communities function, interact with hosts, and influence disease pathways. This is making sequencing services increasingly relevant to pharmaceutical research, precision medicine, academic studies, and gastrointestinal health investigations.
One important driver is the growing use of sequencing within gut microbiome research. As researchers examine relationships between microbial composition, gene expression, and disease mechanisms, sequencing providers are becoming part of broader research workflows rather than serving only as sample-processing vendors. This creates opportunities for service providers that can combine sequencing with sophisticated analytical capabilities.
Sequencing by Synthesis (SBS) is particularly important to this transition because its scalability and high-throughput performance support large microbiome datasets. Its relevance is strengthened by the increasing need to process samples from cohort studies, longitudinal research programs, and pharmaceutical investigations.
The emergence of metatranscriptomic services also signals a broader evolution in the market. These services can examine gene expression and functional microbial activity, giving researchers a more dynamic view of microbiome behavior. Diversigen's metatranscriptomic sequencing and analysis offering illustrates how service providers are expanding beyond conventional sequencing toward deeper functional characterization.
Regional Analysis: North American Scale Meets Asia Pacific Growth
North America currently represents the leading regional market, supported by its established genomics ecosystem, advanced sequencing platforms, and strong demand from biotechnology companies, pharmaceutical organizations, and academic research institutions. The region benefits from an environment in which microbiome research can connect relatively closely with established research infrastructure and pharmaceutical development activities.
Asia Pacific, by contrast, represents the high-growth regional hub, with the market projected to expand at a 12.1% CAGR. The region's momentum reflects expanding genomics capabilities, increasing research activity, and greater outsourcing of sequencing services.
The difference between the two regions reflects distinct stages of market development. North America's position is associated with an established research and commercial ecosystem, while Asia Pacific's growth opportunity is closely connected to expanding sequencing capabilities and increasing utilization of external service providers.
|
Regional Market |
Key Market Characteristics |
Strategic Opportunity |
|
North America |
Established genomics ecosystem and strong biotechnology, pharmaceutical, and academic demand |
Advanced analytical services, clinical research integration, and specialized microbiome workflows |
|
Asia Pacific |
Expanding genomics capabilities, rising research activity, and increasing outsourcing |
Capacity expansion, outsourced sequencing, and broader access to advanced sequencing technologies |
For service providers, Asia Pacific can therefore represent an important expansion pathway, while North America remains central to established demand. The contrasting regional dynamics suggest that companies may need different strategies: deeper application integration in mature markets and scalable service accessibility in faster-growing markets.
Industry Challenge: Turning Sequencing Data Into Actionable Microbiome Insights
A major challenge for microbiome sequencing services is not simply generating sequencing data but converting increasingly complex datasets into standardized, reproducible, and useful biological insights.
Microbiome research can involve large datasets covering microbial composition, functional characteristics, gene activity, and relationships with gastrointestinal or other disease conditions. As sequencing becomes more accessible, the analytical burden can increase alongside the number of samples and research variables.
This challenge is particularly important for academic research institutes, which represent a major end-user segment because they frequently outsource sequencing for microbiome research, cohort studies, and grant-funded projects. Outsourcing can provide access to specialized sequencing infrastructure and analytical workflows, but researchers still require results that are consistent and usable within broader research programs.
The same issue becomes more commercially significant when microbiome sequencing enters pharmaceutical research. Drug discovery programs require sequencing information to fit into clinical research and development workflows. A sequencing provider that delivers data without sufficient analytical context may have limited value to pharmaceutical customers.
Another constraint is the need for increasingly specialized analytical capabilities. Diversigen's expansion into metatranscriptomic sequencing illustrates the industry's response: providers are broadening their services to investigate gene expression and functional microbial activity rather than relying solely on microbial identification.
Technology Comparison: Sequencing by Synthesis vs. Metatranscriptomic Analysis
Two approaches illustrate different dimensions of value creation in microbiome sequencing services: Sequencing by Synthesis (SBS) and metatranscriptomic sequencing and analysis.
Sequencing by Synthesis
SBS is positioned as the fastest-growing technology in the market and has a 60.38% market share. Its strength lies in scalable, high-throughput sequencing performance, making it particularly relevant when researchers need to process substantial numbers of microbiome samples.
Its applications extend across academic research, cohort studies, pharmaceutical research, and other microbiome investigations where scalable sequencing is important.
Metatranscriptomic Sequencing
Metatranscriptomic sequencing addresses a different research need. Rather than focusing primarily on which microorganisms are present, it enables analysis of gene expression and functional microbial activity. This can provide deeper insight into what microbial communities are doing within a biological system.
Diversigen's metatranscriptomic service demonstrates the commercial expansion of this approach into gut microbiome research.
|
Dimension |
Sequencing by Synthesis |
Metatranscriptomic Sequencing |
|
Primary value |
Scalable, high-throughput sequencing |
Functional and gene-expression analysis |
|
Key application |
Large-scale microbiome research and cohort studies |
Functional characterization of microbial activity |
|
Commercial opportunity |
High-throughput outsourced sequencing |
Specialized analytical and functional research services |
|
Strategic relevance |
Supports scalability and accessibility |
Supports deeper biological interpretation |
These approaches should not necessarily be viewed as direct substitutes. SBS addresses the need for scalable sequencing infrastructure, while metatranscriptomics expands the analytical depth that researchers can obtain from microbiome studies. Their coexistence points toward a market in which customers increasingly require both scalable data generation and sophisticated interpretation.
Geographic Opportunity: Four Markets With Strategic Relevance
Several countries stand out because of their connection to established microbiome sequencing companies, research activity, or commercialization of microbiome services.
United States
The United States represents an important market within North America's established genomics ecosystem. Several major market participants are based in the country, including Zymo Research Corporation, MR DNA Laboratory, Rancho BioSciences, CosmosID, and Diversigen. This concentration of industry participants reflects the country's importance to sequencing services, biotechnology research, and microbiome-related commercial activity.
Canada
Canada has an established presence through Microbiome Insights Inc., a company involved in microbiome sequencing services. Its presence highlights Canada's role within the North American microbiome research and service landscape.
Denmark
Denmark is represented by Clinical-Microbiomics A/S, indicating the country's participation in specialized microbiome analysis and sequencing services. Its strategic relevance is particularly connected to the broader European microbiome research ecosystem.
Australia
Australia provides a distinct opportunity through the commercialization of microbiome testing services. Microba introduced a human gut microbiome testing service for comprehensive gastrointestinal analysis and commercialized the solution for healthcare professionals in Australia. This demonstrates how microbiome sequencing capabilities can extend from research services toward applied healthcare and diagnostic-oriented applications.
Competitive Landscape: Service Expansion Is Shaping Competitive Positioning
The competitive environment is characterized by companies expanding beyond basic sequencing toward specialized analytical services, clinical research integration, and application-specific microbiome solutions.
Key participants include Zymo Research Corporation, Clinical-Microbiomics A/S, Mérieux NutriSciences Corporation, Microbiome Insights Inc., BaseClear BV, MR DNA Laboratory, Rancho BioSciences, CosmosID, and Diversigen.
A common strategic direction among these companies is the development of capabilities that increase the value obtained from sequencing data. Diversigen's expansion into metatranscriptomic sequencing and analysis, for example, demonstrates movement toward functional microbiome characterization.
The competitive landscape also shows increasing alignment between sequencing services and clinical development. Locus Biosciences entered a long-term partnership with CosmosID in February 2023 to support microbiome analysis for clinical trial studies. The collaboration integrates microbiome sequencing and analytical capabilities into clinical development workflows, illustrating how sequencing providers can become embedded within therapeutic development programs.
Recent Industry News: Service Innovation and Clinical Integration Gain Momentum
Recent industry developments demonstrate how microbiome sequencing companies are expanding the commercial scope of sequencing and analysis services.
Diversigen — March 2022
In March 2022, Diversigen launched metatranscriptomic sequencing and analysis services for gut microbiome samples. The offering enables research-focused evaluation of gene expression and functional microbial activity. This development expands the analytical depth available to microbiome researchers and supports applications requiring functional characterization rather than microbial identification alone.
Locus Biosciences and CosmosID — February 2023
In February 2023, Locus Biosciences entered a long-term partnership with CosmosID to support microbiome analysis for clinical trial studies. The collaboration integrates advanced microbiome sequencing and analytics into clinical development workflows, reinforcing the growing role of microbiome data in precision therapeutics and clinical research.
Microba — March 2023
In March 2023, Microba introduced a human gut microbiome testing service designed for comprehensive gastrointestinal analysis. The service was commercialized for healthcare professionals in Australia under a branded solution, extending microbiome analysis toward applied healthcare and strengthening the connection between sequencing technologies and gastrointestinal assessment.
Read more about this report @ https://www.fundamentalbusinessinsights.com/industry-report/microbiome-sequencing-services-market-14729
About
Fundamental Business Insights:
Fundamental Business Insights is global market research and consulting company which is engaged in providing in depth market reports to its various types of clients like industrial sectors, financial sectors, universities, non-profit, and corporations. Our goal is to offer the correct information to the right stakeholder at the right time, in a format that enables logical and informed decision making. We have a team of consultants who have experience in offering executive level blueprints of markets and solutions. Our services include syndicated market studies, customized research reports, and consultation.
Contact us:
Robbin Fernandez
Head of Business Development
Fundamental Business Insights and Consulting
Email: sales@fundamentalbusinessinsights.com
Read This Report in Regional Languages -
